Several groups have detected F877L mutations (alternatively described as F876L based on older genomic builds) in the AR LBD following chronic treatment of prostate cancer cell lines with enzalutamide or other second-generation anti-androgens such as ARN-509 [10–12]. Here, AR is linked to Familial prostate cancer.